Clinical trials: Health Resources
Dupuytren's Contracture
Treatment Of Dupuytren's Contracture With Collagenase Clostridium Histolyticum Injection (Xiapex)
This study will evaluate the impact of Xiapex treatment on the range of motion (ROM) of the affected fingers and the patient and physician reported treatment satisfaction and disease severity and their relation to ROM.
- Trial name
- POINT X (NCT01229436)
- Testing
- Xiapex
- Where
- 28 sites in Denmark, France and 6 more
- Volunteers
- 254 people
- Sponsor
- Pfizer
Arthritis,Rheumatoid
Long Term Effects of an Early Response to Certolizumab Pegol (CZP, Cimzia®) in Rheumatoid Arthritis (RA) Patients
To determine if early clinical response at 12 weeks to Certolizumab Pegol (CZP, Cimzia ®) therapy in adult Rheumatoid Arthritis (RA) patients is a predictor of better long term clinical response at 18 months compared with a lack…
- Trial name
- RA-PROACTIVE (NCT01288287)
- Where
- 22 sites in Ireland, United Kingdom
- Volunteers
- 149 people
- Sponsor
- UCB Pharma
Cancer
Clinical Impact and Utility of Digital Health Solutions in Participants Receiving Systemic Treatment in Clinical Practice
This study will evaluate the clinical impact and utility of digital health solutions (DHS) on health outcomes and health-care resource utilization in people receiving systemic anti-cancer treatment (approved or non-approved) in…
- Trial name
- ORIGAMA (NCT05694013)
- Testing
- Roche DPM Module, Atezolizumab SC, Local SOC support
- Where
- 14 sites in Australia, Austria and 3 more
- Volunteers
- 49 people
- Sponsor
- Hoffmann-La Roche
Pulmonary Disease, Chronic Obstructive
A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol
The purpose of this study is to estimate disease-related and all-cause burden and clinical outcomes of interest following initiation of chronic obstructive lung disease (COPD) maintenance therapy with Tiotropium…
- Trial name
- NCT05127304
- Testing
- Trelegy Ellipta, Stiolto Respimat, Furoate/Umeclidinium/Vilanterol
- Where
- United States
- Volunteers
- 11,316 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Thrombocytopenic Purpura, Thrombocytopenia
Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
This is a multi-center prospective observational descriptive study complemented by a retrospective chart review. Patients diagnosed with ITP and currently treated for ITP by a hematologist or hematologist-oncologist will be…
- Conditions
- Idiopathic Thrombocytopenic Purpura, Thrombocytopenia, Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP), Thrombocytopenic Purpura
- Trial name
- NCT00454857
- Testing
- Retrospective Chart Review, Patient-reported Outcome Questionnaires, Physician Survey
- Volunteers
- 326 people
- Sponsor
- Amgen
Inflammatory Bowel Diseases, Depressive Episode
Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health
This study is a large population-based analysis in the United Kingdom (UK) using routine primary care data to investigate the impacts on quality-of-life outcomes and use of healthcare services in people aged 5 - 25 years…
- Conditions
- Inflammatory Bowel Diseases, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorder
- Trial name
- NCT05206734
- Testing
- No specific intervention
- Where
- United Kingdom
- Volunteers
- 19,469 people, healthy volunteers welcome
- Sponsor
- Momentum Data
Rheumatoid Arthritis, Ankylosing Spondylitis
Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary (VALUE)
The objective of this post-marketing observational study (PMOS) was to evaluate the effectiveness of adalimumab plus the AbbVie Care 2.0 patient support program in participants with rheumatoid arthritis (RA), ankylosing…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Psoriasis
- Trial name
- VALUE (NCT02750800)
- Testing
- Adalimumab, AbbVie Care 2.0
- Volunteers
- 427 people
- Sponsor
- AbbVie
Bacterial Infections, Acute Bacterial Skin and Skin Structure Infection
Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
The purpose of this study is to assess the effect of a new critical pathway (use of guideline-based patient identification criteria and for those who meet these criteria, use of dalbavancin) compared to usual care for the…
- Trial name
- NCT03233438
- Testing
- Dalbavancin, Usual Care
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Allergan
Inflammatory Bowel Diseases, Ulcerative Colitis
Healthcare Resource Utilisation, Common Mental Health Problems, and Infections in People With Inflammatory Bowel Disease
Ulcerative colitis and Crohn's disease are the commonest types of inflammatory bowel disease (IBD). Both conditions range in severity from no symptoms to being potentially fatal.
- Conditions
- Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
- Trial name
- NCT03836612
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 95,055 people, healthy volunteers welcome
- Sponsor
- Momentum Data
Ankylosing Spondylitis
Impact of Adalimumab (Humira®) Therapy on Selected Health Care Resource Utilization and Sick Leave in Patients With Ankylosing Spondylitis in Clinical Practice
The purpose of this study was to assess the proportion of AS patients achieving treatment response to adalimumab therapy.
- Trial name
- IDEA (NCT01754727)
- Volunteers
- 452 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Acute Bacterial Skin and Skin Structure Infections
Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
This study will evaluate a new critical pathway (use of guideline-based patient identification criteria and for those who meet these criteria, use of dalbavancin) for the treatment of ABSSSI compared to usual care.
- Trial name
- NCT02961764
- Testing
- Usual Care, Dalbavancin
- Where
- 11 sites in United States
- Volunteers
- 313 people
- Sponsor
- Allergan